Hematology

Latest News

October 31st 2025

Quarter Century Update: Thoughts on Reducing Costs of Goods

By Deborah Phippard, PhD, Renier Brentjens, MD, PhD, Noah Stansfield

Deborah Phippard, PhD, shared her thoughts with Renier Brentjens, MD, PhD, on reducing costs for cell and gene therapy products.

Latest Videos

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Shahzad Raza, MD, on Evaluating CAR-T NXC-201 in R/R Light Chain Amyloidosis

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Jamie Jacobs, PhD, on Using a Digital App to Aid Caregivers for Patients Undergoing Hematopoietic Stem Cell Transplant

Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences

Sarah Hein, PhD, on the Phase 2 Trial for CD5-Directed CAR-T MB-105 in R/R T-Cell Lymphoma

Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,

Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response

Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin

Nirav Shah, MD, MSHP, on Evaluating Zamto-Cel in R/R DLBCL

Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center

Bhagirathbhai R. Dholaria, MD, on Evaluating P-BCMA-ALLO1 in R/R Myeloma

Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University

Mark Hamilton, MD, PhD, on Analyzing PostCAR Myeloid Neoplasms

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)

Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Manali Kamdar, MD, on Transplant Eligibility Versus CAR-T Eligibility

Manali Kamdar, MD, on Sequencing of Treatment in Third-Line R/R LBCL

CME Content

In-Person Event

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

February 7, 2026

Virtual Event

Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

February 17, 2026

In-Person Event

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

February 26-28, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Video

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

André H. Goy, MD; Jorge E. Cortes, MD; Sagar Lonial, MD, FACP

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Amrita Krishnan, MD; Meletios Athanasios (Thanos) C. Dimopoulos, MD; Shaji Kumar, MD; Katja Weisel, MD

More News

Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy

ByDeborah Phippard, PhD,Renier Brentjens, MD, PhD,Noah Stansfield

October 28th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the unpredictability of "living drugs" in the human body and the ongoing development of understanding.

Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?

ByDeborah Phippard, PhD,Renier Brentjens, MD, PhD,Noah Stansfield

October 27th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, shared their thoughts on how streamlined collaboration can help move therapies to patients faster.

Quarter Century Update: Platform Approaches and Industry Investment

ByDeborah Phippard, PhD,Renier Brentjens, MD, PhD,Noah Stansfield

October 27th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed strategies used to streamline development in cell and gene therapy.

Quarter Century Update: Where are the Biggest Bottlenecks Today?

ByDeborah Phippard, PhD,Renier Brentjens, MD, PhD,Noah Stansfield

October 26th 2025

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed the major friction points in cell and gene therapy development and uptake.

Hematology

Latest News

Latest Videos

Shahzad Raza, MD, on Evaluating CAR-T NXC-201 in R/R Light Chain Amyloidosis

Jamie Jacobs, PhD, on Using a Digital App to Aid Caregivers for Patients Undergoing Hematopoietic Stem Cell Transplant

Sarah Hein, PhD, on the Phase 2 Trial for CD5-Directed CAR-T MB-105 in R/R T-Cell Lymphoma

Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response

Nirav Shah, MD, MSHP, on Evaluating Zamto-Cel in R/R DLBCL

Bhagirathbhai R. Dholaria, MD, on Evaluating P-BCMA-ALLO1 in R/R Myeloma

Mark Hamilton, MD, PhD, on Analyzing PostCAR Myeloid Neoplasms

Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Manali Kamdar, MD, on Transplant Eligibility Versus CAR-T Eligibility

Manali Kamdar, MD, on Sequencing of Treatment in Third-Line R/R LBCL

CME Content

Show Me the Data: How Today’s Evidence Is Shaping Tomorrow’s Management and Prophylaxis of Chronic GVHD

Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

More News

Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy

Quarter Century Update: How can Partnerships Between Academia, Biotech, and Pharma be Better Structured?

Quarter Century Update: Platform Approaches and Industry Investment

Quarter Century Update: Where are the Biggest Bottlenecks Today?

CGTLive®’s Weekly Rewind – October 24, 2025

Quarter Century Update: What Were the Most Significant Inflection Points or Breakthroughs in the Field?

Around the Helix: Cell and Gene Therapy Company Updates – October 22, 2025

CGTLive®’s Weekly Rewind – October 17, 2025

Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025

CGTLive®’s Weekly Rewind – October 10, 2025

Verismo Therapeutics’ Trial for CAR-T SynKIR-310 Doses First Patient With Follicular Lymphoma

Avobis Bio's Crohn Disease Cell Therapy AVB-114 Garners FDA RMAT Designation

Around the Helix: Cell and Gene Therapy Company Updates – October 8, 2025

Orca Bio’s BLA for Hematologic Malignancy Cell Therapy Orca-T Accepted by FDA With Priority Review

Rocket Pharmaceuticals Pulls BLA for Fanconi Anemia Gene Therapy RP-L102

CGTLive®’s Weekly Rewind – October 3, 2025

Umoja Biopharma's In Situ CAR T Therapy UB-VV111 Fast-Tracked for Several R/R B-Cell Malignancy Indications

Around the Helix: Cell and Gene Therapy Company Updates – October 1, 2025

News in Cell and Gene Therapy for Rare Cancer Day 2025

CGTLive®’s Weekly Rewind – September 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – September 24, 2025

CGTLive®’s Weekly Rewind – September 19, 2025

Phase 1/2 Trial for Immix Biopharma’s AL Amyloidosis CAR T NXC-201 Hits Over 50% Enrollment

Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025

ImmunoLogic, Episode 6: "Tailor-Made Immunity: The Promise of Personalized Neoantigen Vaccines” With Stephen Schoenberger, PhD

Trending on CGTlive®

Around the Helix: Cell and Gene Therapy Company Updates – January 28, 2026

Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial